Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q96P53
UPID:
WDFY2_HUMAN
Alternative names:
Propeller-FYVE protein; WD40- and FYVE domain-containing protein 2; Zinc finger FYVE domain-containing protein 22
Alternative UPACC:
Q96P53; B1AL86; Q96CS1
Background:
WD repeat and FYVE domain-containing protein 2, also known as Propeller-FYVE protein, plays a crucial role in cellular processes. It mediates interactions between kinase PRKCZ and VAMP2, enhancing PRKCZ-dependent phosphorylation of VAMP2. This protein is instrumental in adipocyte differentiation, aiding in the phosphorylation and inactivation of FOXO1 by AKT1, and is vital for insulin-stimulated AKT2 signaling and glucose uptake.
Therapeutic significance:
Understanding the role of WD repeat and FYVE domain-containing protein 2 could open doors to potential therapeutic strategies.